BioRestorative Therapies
BRTX
13 hedge funds and large institutions have $900K invested in BioRestorative Therapies in 2022 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 1 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
0.89% less ownership
Funds ownership: 9.82% → 8.93% (-0.89%)
7% less funds holding
Funds holding: 14 → 13 (-1)
22% less capital invested
Capital invested by funds: $1.16M → $900K (-$256K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$15.8K |
| 2 |
SG
StoneX Group
New York
|
+$10.5K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$5.98K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$4.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Ayrton Capital
Westport,
Connecticut
|
-$62.4K |
| 2 |
BFM
Boothbay Fund Management
New York
|
-$61.4K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$4.86K |
| 4 |
SPIA
Steward Partners Investment Advisory
New York
|
-$3.11K |
| 5 |
IA
IFP Advisors
Tampa,
Florida
|
-$2K |
BRTX Hedge Fund Activity: Q4 2022 in Review
13 of the 6,238 institutional investors tracked by Wall St. Rank reported a position in BioRestorative Therapies (BRTX) for Q4 2022, worth a combined $900K — down 22% from $1.16M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of BRTX and 0 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 4 added.
The largest buyer was Cambridge Investment Research Advisors, adding an estimated $15.8K. The largest seller was Ayrton Capital, cutting an estimated $62.4K.
- 13 institutional investors held BioRestorative Therapies (BRTX) as of Q4 2022, down from 14 in Q3 2022.
- Funds reported $900K of BioRestorative Therapies stock for Q4 2022, down 22% quarter-over-quarter.
- 0 funds opened new BioRestorative Therapies positions in Q4 2022 and 1 closed out, a net change of -1 holder.
- The largest BioRestorative Therapies buyer in Q4 2022 was Cambridge Investment Research Advisors, an estimated $15.8K added.
- The largest BioRestorative Therapies seller in Q4 2022 was Ayrton Capital, an estimated $62.4K sold.
Based on aggregated 13F filings for Q4 2022.